TY - JOUR
T1 - A randomized trial of treatment for multisystem Langerhans' cell histiocytosis
AU - Gadner, Helmut
AU - Grois, Nicole
AU - Arico, Maurizio
AU - Broadbent, Valerie
AU - Ceci, Adriana
AU - Jakobson, Ake
AU - Komp, Diane
AU - Michaelis, Jörg
AU - Nicholson, Stacy
AU - Pötschger, Ulrike
AU - Pritchard, Jon
AU - Ladisch, Stephan
N1 - Funding Information:
Supported in part by the Histiocytosis Association of America and the Children’s Cancer Research Institute (CCRI), St Anna Children’s Hospital, Vienna, Austria.
PY - 2001
Y1 - 2001
N2 - Objective: To compare 2 active agents, vinblastine and etoposide, in the treatment of multisystem Langerhans' cell histiocytosis (LCH) in an international randomized study. Study design: One hundred forty-three untreated patients were randomly assigned to receive 24 weeks of vinblastine (6 mg/m2, given intravenously every week) or etoposide (150 mg/m2/d, given intravenously for 3 days every 3 weeks), and a single initial close of corticosteroids. Results: Vinblastine and etoposide were equivalent (P ≥ .2) in all respects: response at week 6 (57% and 49%); response at the last evaluation (58% and 69%); toxicity (47% and 58%); and probability of survival (76% and 80%), of disease reactivation (61% and 55%), and of developing permanent consequences (39% and 51%) including diabetes insipidus (22% and 23%). LCH reactivations were usually mild, as was toxicity. All children ≥2 years old without risk organ involvement (liver, lungs, hematopoietic system, or spleen) survived. With such involvement, lack of rapid (within 6 weeks) response was identified as a new prognostic indicator, predicting a high (66%) mortality rate. Conclusions: Vinblastine and etoposide, with one close of corticosteroids, are equally effective treatments for multisystem LCH, but patients who do not respond within 6 weeks are at increased risk for treatment failure and may require different therapy.
AB - Objective: To compare 2 active agents, vinblastine and etoposide, in the treatment of multisystem Langerhans' cell histiocytosis (LCH) in an international randomized study. Study design: One hundred forty-three untreated patients were randomly assigned to receive 24 weeks of vinblastine (6 mg/m2, given intravenously every week) or etoposide (150 mg/m2/d, given intravenously for 3 days every 3 weeks), and a single initial close of corticosteroids. Results: Vinblastine and etoposide were equivalent (P ≥ .2) in all respects: response at week 6 (57% and 49%); response at the last evaluation (58% and 69%); toxicity (47% and 58%); and probability of survival (76% and 80%), of disease reactivation (61% and 55%), and of developing permanent consequences (39% and 51%) including diabetes insipidus (22% and 23%). LCH reactivations were usually mild, as was toxicity. All children ≥2 years old without risk organ involvement (liver, lungs, hematopoietic system, or spleen) survived. With such involvement, lack of rapid (within 6 weeks) response was identified as a new prognostic indicator, predicting a high (66%) mortality rate. Conclusions: Vinblastine and etoposide, with one close of corticosteroids, are equally effective treatments for multisystem LCH, but patients who do not respond within 6 weeks are at increased risk for treatment failure and may require different therapy.
UR - http://www.scopus.com/inward/record.url?scp=0035018142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035018142&partnerID=8YFLogxK
U2 - 10.1067/mpd.2001.111331
DO - 10.1067/mpd.2001.111331
M3 - Article
C2 - 11343051
AN - SCOPUS:0035018142
SN - 0022-3476
VL - 138
SP - 728
EP - 734
JO - Journal of Pediatrics
JF - Journal of Pediatrics
IS - 5
ER -